Dear Stakeholders,

One behalf of everyone at the Daiichi Sankyo group of companies, I would like to express my sincere gratitude for your dedication to driving our business forward.

For over 120 years, Daiichi Sankyo has dedicated itself to the creation of innovative medicines and consistently asks what else we can do for patients. This enduring commitment has enabled us to deliver essential treatments to those who suffer from illness. The DNA of drug discovery that has been passed down since our founding is now positioned as our greatest strengths: our science and technology.

We have fostered a corporate culture that respects the free-thinking of our researchers, allowing them to challenge uncertain fields and unexplored areas driven by their scientific curiosity and hypotheses. The unique knowledge and experience generated from this environment serves as a new source of innovation, and such enthusiasm for innovation is firmly rooted in patient centricity.

By providing effective treatments to more patients, we can contribute to the overall health of society, aligning with our Purpose, which is to contribute to the enrichment of quality of life around the world. By truly living our corporate slogan, —Passion for Innovation. Compassion for Patients—, we drive patient centricity initiatives across the entire value chain.

Currently, we are expanding our pipeline to realize our 2030 Vision of becoming an innovative global healthcare company contributing to the sustainable development of society, and to drive growth beyond that. Needless to say, what truly supports this growth is our people. It is our people who strengthen the entire value chain to develop innovations and deliver them as medicines to patients.

Our corporate culture, known as One DS Culture, is creating a highly engaged and diverse workforce, fostering an environment that generates competitiveness and advantages within our organization. We will keep enhancing our investment in people, continuously nurturing and strengthening them to contribute to future growth.

Traditionally, Japan has a concept known as "Sanpo Yoshi," or the “Three-Way Good,” which means "good for the seller, good for the buyer, and good for society." In modern terms, this represents the creation of shared value with multiple stakeholders, which is precisely Daiichi Sankyo's value co-creation model.

We aim to grow as a company by realizing our Purpose and contributing more to our patients. The resources obtained from this growth will be returned to all our stakeholders in a balanced manner, including patients and society. It is crucial for us to be a company that is recognized as continuously meeting the expectations of society, where all stakeholders can benefit from our growth. As a leader in Daiichi Sankyo, I will continue to take responsibility and put this into practice.

I strive for the better lives of our patients and a better society and seek your continued support as we embark on this journey.

Hiroyuki Okuzawa 
Representative Director
President and CEO